donanemab
Sign in to saveDonanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- Amyloid beta
- Drug.tradename
- Kisunla
- Drug.MedlinePlus
- a624048
- Drug.DailyMedID
- Donanemab
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- DX05
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1931944-80-7
- Drug.DrugBank
- DB16647
- Drug.UNII
- 1ADB65P1KK
- Drug.KEGG
- D11500
- Drug.synonyms
- LY3002813, donanemab-azbt
- Drug.C
- 6452
via Wikipedia infobox
Article
19 sectionsContents
- Medical uses
- Adverse effects
- Cerebral edema
- History
- Phase I
- First study
- Side effects
- Second study
- Side effects
- Trailblazer-alz
- Results
- Side effects
- Phase III
- Society and culture
- Legal status
- Economics
- Names
- Research
- References
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company.
The most common side effects include amyloid-related imaging abnormalities, which are brain hemorrhages and brain swelling, which can cause strokes, seizures, falls and trouble thinking. Brain hemorrhage and swelling occurred in 36.8% of people taking donanemab and 14.9% of people taking placebo. Headache and allergic reactions to the medication were other common side effects.